Alliance With Hartford Hospital Will Preserve Crucial Academic And …
The News Review:
- Alliance With Hartford Hospital Will Preserve Crucial Academic And …
- ACR Comments on NEJM Article on Globalization of Clinical Research
- Some of your body’s cells have a ‘license to kill’
- Transparency Globalization Growing in Clinical Research Enhanced …
- Questions f Ethics Quality Cloud Globalization f Clinical Trials
Alliance With Hartford Hospital Will Preserve Crucial Academic And …
Hartford Courant United States -
Failure to act would jeopardize the status and the research capacity of. Furthermore it would mean the continued operation of an inefficient obsolete Dempsey Hospital with its ongoing operating deficits which ensures its eventual closure with loss of on-site capacity for teaching and clinical research. The status quo is unacceptable. The cost of any eventual action by the state to sustain quality medical education and research and to achieve high-quality medical care will steadily increase. The efforts of the health center and its hospital partners over the past eight months achieved a level of collaboration that if fully implemented far exceeds what anyone envisioned only one year ago. All parties to this proposal can benefit by creating a regional health care system that will serve as an economic engine and a health care destination.
ACR Comments on NEJM Article on Globalization of Clinical Research
PR Newswire (press release) NY -
A well-trained global investigator network is in the best interest of all participants in the drug development process. However the globalization of the clinical trials enterprise is a complex endeavor involving many factors. Unfortunately the authors’ ignored one of the primary drivers behind the globalization of clinical research: the limited participation rate in clinical trials in the United States and Western Europe. According to the non-profit Center for Information & Study on Clinical Research Participation 80% of clinical trials in the United States are delayed at least one month because of unfulfilled enrolment. The ramifications of this limited participation are clear. According to the National Cancer Institute fewer than 5% of cancer patients participate in clinical trials; but if the participation rate doubled to just 10% studies could be completed in one year rather than the typical three-to-five years. ACR and its members work extensively to increase clinical trial participation in the U.
Some of your body’s cells have a ‘license to kill’
The Miami Herald FL -
30 issue of the Proceedings of the National Academy of Sciences. -A possible method to make NK cells even more deadly executioners. Andre Veillette a cancer researcher at the Clinical Research Institute of Montreal has identified a molecule named CRACC on the surface of NK cells that he said “augments their ability to kill abnormal cells. “A drug that stimulates CRACC would “increase their killer function” Veillette said. NK cells are being generated constantly in bone marrow. They prowl through the blood and lymph systems searching for signs of infected or cancerous cells. When they find one they latch on to it and attempt to execute it leaving nearby healthy cells alone.
Transparency Globalization Growing in Clinical Research Enhanced …
Modern Medicine NJ -
19 (HealthDay News) — All clinical trial data and the U. Food and Drug Administration database should be publicly available and global clinical research should be conducted in relevant populations for potential applications of the intervention according to two articles published in the Feb. 19 issue of the New England Journal of Medicine. In the first article Alastair J.
Related from Macintoshpost: MacPractice DDS 3.6 features restorative chart enhanced dental …
Questions f Ethics Quality Cloud Globalization f Clinical Trials
eMaxHealth.com NC -
-based pharmaceutical companies are moving their clinical trials overseas at warp speed raising questions about ethics quality control and even the scientific value of their findings for people back in the U. Many of the trials are taking place in developing countries in Eastern Europe and Asia where study participants are often poorer and less educated than are study participants in the U. according to researchers at Duke Clinical Research Institute (DCRI). “The FDA is supposed to provide oversight for such trials but it simply wasn’t designed to handle this kind of situation” says Kevin Schulman MD the senior author of the report appearing in the New England Journal of Medicine. Schulman says the number of Food and Drug Administration investigators based outside the U.
Written by admin on February 22nd, 2009 with
no comments.
Read more articles on News.